MedTrace Logo

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04869488 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2025-01-24

No results posted yet for this study

Summary

Main research purpose: To evaluate the effectiveness of Fluzoparib combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

Fluzoparib

Fluzoparib Orally twice daily（Cohort 1、Cohort 4）

DRUG

Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets

Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）

DRUG

Fluzoparib Combined With Apatinib

Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2023-02-14
Completion
2023-02-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869488 on ClinicalTrials.gov